ADC Therapeutics SA (ADCT) vs InflaRx N.V. (IFRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed ADC Therapeutics SA (ADCT) over the past year, gaining 4.1% versus a loss of 65.0%. Over five years, IFRX leads with a -38.1% price change compared with -93.8% for ADCT. InflaRx N.V. is the larger company by market cap ($235.8 million vs $220.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | IFRX |
|---|---|---|
| Share price | $1.73 | $1.60 |
| Market cap | $220.87M | $235.79M |
| 1-day change | +8.81% | +4.58% |
| YTD return | -54.96% | +51.49% |
| 1-year return | -64.98% | +4.08% |
| 5-year return | -93.76% | -38.06% |
| EPS (TTM) | $-0.60 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $2.95 |
| 52-week low | $0.78 | $0.798 |
| Distance from 52-week high | -65.26% | -45.74% |
| Analyst consensus | none | none |
| Avg. price target upside | +92.49% | +380.00% |
| Average volume | 1.43M | 798.72K |
| Shares outstanding | 127.67M | 147.37M |
| Employees | 188 | 65 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed ADCT by 69.1 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees
ADCT vs IFRX FAQ
Which is bigger, ADC Therapeutics SA or InflaRx N.V.?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $235.79M compared with $220.87M for ADC Therapeutics SA (ADCT).
Which stock has performed better over the past year, ADCT or IFRX?
IFRX returned +4.08% over the past 12 months, compared with -64.98% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and InflaRx N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.